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The decrease in NKG2D+ Natural Killer cells in peripheral 
blood of patients with metastatic colorectal cancer
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Abstract: Background: Natural killer (NK) cells play important roles in the immune defense against tumors such 
as colorectal cancer. In humans, NKG2D is an activating immune receptor constitutively expressed in most 
cytotoxic lymphocytes including NK and CD8+ T cells. In this study, the expression of NKG2D molecule was 
investigated in peripheral blood NK cells from colorectal cancer patients and compared with healthy subjects. 
Methods: We studied 21 non-metastatic (low-grade), 17 non-metastatic (high-grade), 16 metastatic colorectal 
cancer patients, and 24 healthy controls. Peripheral blood samples were obtained to isolate peripheral blood 
mononuclear cells (PBMCs) and the percentage of peripheral blood NKG2D+CD3-CD56+ NK cells was ana-
lyzed by fl ow cytometry. The expression of NKG2D at mRNA level was also measured by real-time PCR in 
both, patients and control subjects. Results: The results showed a signifi cant reduction in the percentage of 
NKG2D+NK cells as well as NKG2D mRNA expression in peripheral blood of metastatic colon cancer patients. 
Conclusion: This result suggests that decreased expression of activating NKG2D receptor in metastatic colorectal cancer 
might compromise NK cell function and allow tumor to evade immunity (Tab. 3, Fig. 4, Ref. 33). Text in PDF www.elis.sk. 
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Introduction
Colorectal cancer, also called colon cancer, is the third most 
commonly diagnosed cancer in the world, but its prevalence is 
higher in developed countries (1, 2). Based on Tumor/node/me-
tastasis (TNM) system, this cancer is divided into four stages (I, 
II, III, and IV), which are considered non-metastatic (I–III) or 
metastatic (IV) CRC stages (3). Similar to other cancers, tumor 
grading of colorectal cancer includes low and high grade.
Natural Killer (NK) cells are large granular lymphocytes 
(LGLs), which play an important role in primary protection from 
viruses and tumors. For this purpose, NK cells apply both activat-
ing and inhibitory receptors, which regulate their activity through 
a balance between inhibitory and stimulatory signal cascades. 
NKG2D (Natural Killer Group 2D; CD314), also mentioned as 
NKG2D receptor, belongs to C-type lectin-like superfamily and 
is expressed on the surface of NK cells as the primary activating 
receptor. It is also expressed on CD8+Tcells, γδT cells and some 
CD4+T cells as a co-stimulator receptor (4–6).
The NKG2D ligands (NKG2DLs) consist of a diverse array 
of proteins that are structurally related to MHC class I. Several 
studies indicate that NKG2D engagement by NKG2DLs induces 
proliferation, survival, and cytotoxic activity in NK cells (7, 8). 
Consequently, NKG2D/NKG2DLs interaction may represent an 
important activation to launch the immune strong response against 
malignant cells (9). NKG2D ligands are also extensively expressed 
on solid tumors and some forms of leukemia through induction of 
cancer-related pathways and oncogenes, but not on normal cells 
(10, 11). Hence, owing to the loss of these ligands in normal cells 
and their expression in some types of cell stress such as in viral 
infections and cancers, NKG2D is considered as one of molecules 
involved in immune surveillance (12–14).
Interestingly, it has been shown that NKG2DLs shedding from 
tumor cell surface happens in diverse malignant cancers, includ-
ing advanced hepatocellular carcinoma, colon, prostate, renal, 
and breast cancer, as well as in hematopoietic tumors (15–19). 
Release of these ligands in serum may end in down-modulation 
of NKG2D through facilitating NKG2D internalization and lyso-
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somal degradation, and this strategy has been assumed to be an 
interesting mechanism applied by cancer cells to evade the tumor 
immunosurveillance (20).
In the current research, we studied NKG2D expression in pe-
ripheral blood NK cells acquired from metastatic, non-metastatic 
colorectal cancer patients, and healthy individuals. 
We postulated that the percentages of NKG2D+ NK cells were 
diminished concomitantly with progression of the cancer.
Methods 
Samples from patients and controls 
Heparinized peripheral blood was obtained from 54 patients 
with colorectal cancer attending the gastroenterologic clinic of 
Al-zahra, khanevadeh, and seid-al-shohada hospitals, affi liated 
to Esfahan University of Medical Sciences, as well as from 24 
healthy volunteers matched as to age and sex (Tab. 1). Hema-
tologic features of patients and healthy subjects are compared 
among the groups in Table 2, including white blood cell count 
(WBC), total lymphocytes, red blood cell count (RBC), platelet 
count (PLT), hemoglobin (Hb) and hematocrit (Hct). Written 
consent was obtained from all patients and healthy controls, and 
the study was approved by the Ethical Committee of Esfahan 
University of Medical Sciences. Disease diagnosis was based on 
symptoms including constipation in recent 6 months, history of 
familial polyposis, anus bleeding and positive colonoscopy re-
sults in relation to non-metastatic patients, and history of colorec-
tal cancer with current tumor dissemination to other organs in 
metastatic patients. Patients with established colonoscopic and 
histopathological diagnosis of non-metastatic (low-grade), non-
metastatic (high-grade) and metastatic colorectal cancer were 
enrolled in this study. Also, in our research, the scale applied to 
grading of non-metastatic colorectal cancer contained low grade 
(where the tissue of cancer was similar to normal colorectal can-
cer) and high grade (where the tissue of cancer appeared to be 
very abnormal).
Peripheral blood mononuclear cell (PBMC) isolation 
The most common method for PBMC isolation, Ficoll-
Hypaque PBMC separation, was applied. Briefl y, fresh periph-
eral whole blood samples with heparin coagulant were diluted 
in one-to-one ratio by PBS/2%FBS solution. Then, diluted blood 
sample was gently laid on Ficoll- Hypaque layer (sigma, St Louis, 
MO, USA) and fi nally PBMC was separated from this solution 
via density centrifugation at 2800 rpm for 20 min. The viability 
of isolated cells was more than 95 % as assessed by Trypan blue 
exclusion test. 
Flow cytometry
PBMC staining for FACS analysis was done with optimized 
amount of the following fl uorochrome conjugated mAbs: CD3-
PerCp, CD56-FITC, NKG2D-PE, PerCp Mouse IgG1 κ Isotype 
Control, FITC Mouse IgG2b κ Isotype Control, and PE Mouse 
IgG1 κ Isotype Control. All mAbs with the exception of NK-
G2D-PE and PE Mouse Isotype control (eBioscience; San Diego, 
CA; USA) were purchased from BD Bioscience (San Jose,CA, 
USA). The isolated cell suspension was adjusted at 105–106 cells/
ml and incubated with anti CD3, anti CD56 and anti NKG2D for 
30 min at 4 °C. Simultaneously, daily, we incubated a tube with 
isotype controls for these three color staining. Ultimately, cells 
were fi xed with 0.5 % paraformaldehyde solution if evaluation 
was delayed. A three-color analysis on FACS caliber (BD) was 
used to demonstrate the NKG2D expression on CD56+CD3- as 
NK cells. 
Feature Normal Non-metastatic 
(low-grade)
Non-metastatic 
(high-grade)
Metastatic
Total number 24 21 17 16
Sex female 10 9 6 4
male 14 12 11 12
Age (years) minimum 29 40 43 44
maximum 65 71 71 72
Tab. 1. Demographic characteristics of patients and healthy subjects.
Primer sequence Target
GGC TCC ATT CTC TCA CCC A NKG2D-F-primer
TAA AGC TCG AGG CAT AGA GTG C NKG2D-R-primer
TCCAAGGCTCAGGTACTTCAAAG NKp44-F-primer
GGGCGGGTACTGGCATCT NKp44-R- primer
GAA GGT GAA GGT CGG AGT GAPDH-F-primer
CAT GGG TGG AAT CAT ATT GGA A GAPDH-R-primer
Tab. 3. Primer sequences used in Real-time PCR test F: Forward, 
R: reverse.
 Healthy
 Control
 Non - metastatic
 (low-grade)
 Non-metastatic
 (high-grade)
 Metastatic
WBC ×103/μl 6.85±1.53 6.56±2.21 6.85±1.83 7.8±2.33
Lymphocyte ×103/μl 2.6±0.88 2.06±0.67 3.23±0.61 4.48±0.77
RBC ×106/μl 5.11±0.52 4.72±0.56 4.75±0.66 4.79±0.55
PLT ×103/μl  211±59  195±53  182±67  225±99
Hb g/dl 14.43±1.99 12.66±1.62 12.52±2.13  2.64±1.79
Hct %  44.89±5.69  39.7±4.7  38.56±1.34  40.97±5.91
Tab. 2. Hematologic parameters of patients and healthy subjects.
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Real-time PCR analysis
Cell pellet was separated from whole blood after using cell 
lysing buffer and centrifuging. Then, total RNA was extracted by 
Guanidinium thiocyanate-phenol-chloroform method (Sinagen, 
Iran). Consequently, oligo (dT) primed cDNA (Vivantis Tech-
nologies, Malysia) was prepared and relative quantifi cation value 
(RQ value) of gene expression was performed in real-time PCR 
using SYBR green. To internally standardize the levels of gene 
expression, the GAPDH housekeeping gene was used. All PCR 
amplifi cation was performed using the ABI Real Time PCRSystem 
(Perkin-Elmer Applied Biosystems, California, USA) in a 25 μl 
fi nal volume, using primers at 300 nM. PCR reactions were per-
formed in triplicate as follows: 55 °C for 2 min, 95 °C for 10 min, 
and 40 cycles of 95 °C for 15 s, and 60 °C for 1 min.
The fl uorescent signal was measured and plotted during each 
60 °C annealing and extension step for all samples. Using the cycle 
threshold (the number of PCR cycles required for the fl uorescent 
dye to be detectable) and the constructed standard curve for each 
cDNA, the relative amounts of GAPDH and NKG2D cDNA in 
each sample were determined. Primers are summarized in Table 3.
Statistics
Statistical analysis was performed using the SPSS21 statisti-
cal software. The results were evaluated by One-way ANOVA and 
Kruskal-Wallis tests. Probability values of less than 0.05 were re-
garded signifi cant. The results presented in text, tables and fi gures 
represent mean standard deviation (SD).
Results
Subjects
Based on TNM system, patients were classifi ed either as non-
metastatic (low-grade) (n = 21), non-metastatic (high-grade) (n = 
17), or metastatic (n = 16) groups (Tab. 2). All patients were en-
Fig. 1. Gating on NK cells based on CD3-CD56+ panel and mean±SD 
in relation to NK cell percentage in lymphocytes of PBMC in study 
groups: A) control B) non-metastatic (low grade) C) non-metastatic 
(high grade) and D) metastatic of colorectal cancer.
A B
C D
Fig. 2. Three color fl owcytometric analysis of NKG2D+CD3-CD56+ NK cells in representative patient and control samples. Lymphocytes were 
gated in FSc (Forward light scatter)-SSc (Side light scatter) dot plot and then CD3-CD56+ gated in CD3-PerCp intensity vs. CD56-FITC in-
tensity. Histograms show the frequency of NKG2D+NK cells and MFI of NKG2D on these cells in the upper of each histogram. Colorless his-
tograms represent isotype control.
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rolled in our study before surgery or chemotherapy to minimize 
the negative effect of these factors on their immune status. 
Hematologic parameters
Among these features, the lymphocyte count and Hct in pe-
ripheral blood of patients with metastatic cancer showed signifi -
cant increase ((4.48 ± 0.77) ×103/μl; p < 0.001 and 40.97 ± 5.91 
%; p < 0.001, respectively) when compared with non-metastatic 
patients and healthy controls.
Gating of NK cells based on CD3-CD56+ panel
The percentage of NK cells in peripheral blood lympho-
cytes of colorectal cancer patients showed a rising trend and it 
was signifi cantly higher in metastatic colorectal cancer patients 
(30.06±13.94%) than in control subjects (15.75 ± 9.69 %; p < 
0.0001) (Fig. 1).
Reduced numbers of NKG2D+ NK cells 
As shown in Figure 1, the percentage of NKG2D+ NK cells in 
all patients and healthy donors was determined using fl ow cytom-
etry. A decreased percentage of NKG2D+ NK cells was detected 
in patients with non-metastatic (high-grade) and metastatic colon 
cancer compared to controls; however, only the decrease in the 
percentage of NKG2D+ NK cells in metastatic group was statisti-
cally signifi cant (p = 0.02) (Fig. 2). 
Down-regulation of NKG2D mRNA expression 
Although NKG2D mRNA levels were decreased during 
colorectal cancer progression, it was diminished signifi cantly 
only in the metastatic group (0.82 ± 0.013 RQ value) compared 
to the normal group (p < 0.001) (Fig. 3). 
Discussion
NK cells play critical role in immune surveillance and elimina-
tion of tumor cells. These cells can distinguish stressed cells from 
normal cells and maintain self-tolerance through function of their 
activating and inhibitory receptors. In normal conditions, the inhib-
itory receptors bind to their ligands (self- MHC class I molecules) 
on surface of healthy host cells and lead to NK cell inhibition; as 
opposed to the latter, in stressed cells, the decreased expression 
of ligands for inhibitory receptors (missing-self) or increased ex-
pression of ligands for stimulatory receptors (induced-self) cause 
NK cell activation and tumor cell lysis (21–23).
In our research, a signifi cantly rising trend was shown in 
metastatic colon cancer patients (Fig. 1). Different studies display 
various changes in percentage of peripheral blood NK cells in di-
verse cancers. In one study on colon cancer, all patients without 
metastasis displayed a signifi cantly increased percentage of NK 
cells in the peripheral blood when compared to control patients. 
In contrast, patients with already established metastasis did not 
display changes in the number of NK-cells when compared to con-
trol patients (24). Garcia-Iglesias clarifi ed that although peripheral 
blood NK cell percentage did not signifi cantly vary among HGSIL 
(High grade squamous intraepithelial lesions), LGSIL (Low-grade 
squamous intraepithelial lesions) and healthy women, patients with 
invasive squamous cervical cancer had signifi cantly lower NK cell 
percentage in comparison with HGSIL patients (25). The other 
study on breast cancer indicated a signifi cant increase in the total 
NK cell percent in invasive ductal carcinoma (IDC) compared to 
that in normal group (26).
NKG2D molecules are one of important receptors on NK 
cells and cytotoxic T cells (CD8+ and γδT) and their binding to 
the ligands can activate alone cytotoxicity of these cells (27). It 
has been previously shown that the expression of NKG2D on NK 
cells from colon cancer patients was decreased in comparison with 
Fig. 3. The percentage of NKG2D+NK cells were reduced by progres-
sion of colon cancer. p < 0.05 was considered signifi cant.
Fig. 4. NKG2D expression in the peripheral blood of patients and con-
trol groups. A sample from the normal subjects was applied as a cali-
brator after normalizing versus GAPDH. Bars represent the mean±SD 
relative expression as RQ value. p < 0.05 was considered signifi cant.
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normal donors (16). Moreover, a signifi cant lower expression of 
NKG2D on NK cells from cervical cancer carcinoma (metastatic) 
patients in comparison with healthy women was reported previ-
ously (25). In a similar manner, we observed that the percentages 
of NKG2D+NK cells as well as their mRNA expression were de-
creased during tumor progression, indicating a signifi cant decrease 
in metastatic colon cancer patients (Fig. 4). 
Down-regulation of NKG2D expression on NK cells in met-
astatic colorectal cancers could be considered a tumor evading 
mechanism, which has been reported for several tumors previ-
ously. It has been shown that reduced expression of NKG2D on 
NK cells was correlated with high serum levels of major histo-
compatibility complex class I-related chain A (MICA), the most 
important membrane-bounded NKG2DL in high-grade cancers 
(28). MICA is prevalent only in low-grade cancers and may be 
released into the tumor stroma and circulation in high-grade can-
cers as soluble MICA (sMICA) (29). In fact, soluble MICA is re-
garded as a soluble decoy receptor and it is not likely produced in 
the early stages of cancer. As a result, primary cancers with low 
number of mutations are good targets for NK and CD8+T cells 
activity, while secondary mutations that occur in the later stages of 
cancer mediate sMICA production or silencing the ligand expres-
sion and provide a possibility of immunologic evasion for cancer 
cells. Thus, MICA-NKG2D works like a double-edged sword in 
various stages of cancer (29, 30). 
TGF-α1 could also infl uence the surface NKG2D expression. 
It has been reported that TGF-β1 present in plasma of lung and 
colorectal cancer patients affects NK cell activity via NKG2D 
down-modulation (31). By silencing TGF-β1 and -β2 genes in 
malignant glioma cells, Friese et al showed that these tumor cells 
did not down-regulate the NKG2D expression on NKL cells (a 
NK cell line). Furthermore, a strong surface MICA expression on 
tumor cells was also observed (32). These results support the fi rm 
role of TGF-β in the MICA/NKG2D pathway. It is well known 
that this cytokine is largely produced by many cancer cells and it 
is also common with high levels in colorectal cancer patients (33).
In conclusion, our study reveals reduced numbers of NKG2D+ 
NK cells in patients with metastatic colorectal cancer by fl ow cy-
tometric assay. Moreover, since NKG2D-NKG2DLs system re-
quires precise regulation. Therefore inappropriate expression of 
NKG2D ligands might compromise NK cell activation, and it can 
be considered a double-edged sword role for this system in vari-
ous stages of colorectal cancer. Targeting specifi c factors involved 
in MICA shedding from cell surfaces or directly blocking sMICA 
in circulation could be a clinically important strategy to boost the 
anti-tumor response against colorectal cancer. 
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